The PLK1 inhibitor, BI2536 and the alkylating agent, cisplatin, promoted the development of tubular squamous cell carcinoma (ESCC) into pyroptosis and inhibited tumour progression by augmenting the caspase‐3/GSDME pathway.179. Here, GSDME is linked to neoplasm.